Retrophin Inc. appointed Eric Dube president and CEO, effective Jan. 4.
Prior to joining Retrophin, Dube was president of North America at ViiV Healthcare, a GlaxoSmithKline PLC unit.
Dube succeeds Stephen Aselage, who is retiring. Aselage, who has been CEO since 2014, will continue to serve on Retrophin's board.
Dube will also serve on the board of the San Diego-based biopharmaceutical company, which develops therapies for rare diseases.